Fong Wang
About
Fong Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Fong Wang has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Fong Wang's work include Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Renal cell carcinoma treatment (6 papers). Fong Wang is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Renal cell carcinoma treatment (6 papers). Fong Wang collaborates with scholars based in United States, France and United Kingdom. Fong Wang's co-authors include De Phung, John N. Forrest, Eberhard Schlatter, R. Greger, Andrew Krivoshik, Simon Chowdhury, Neal D. Shore, Laurence Klotz, Arnauld Villers and Axel Heidenreich and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.
In The Last Decade
Fong Wang
26 papers receiving 1.1k citations
Hit Papers
Peers
Fong Wang
Amy Lin United States
Rajesh Shinghal United States
Maneesha Mehra United States
Kim M. Smits Netherlands
G Gardani Italy
Sergio Crispino Italy
Kathrin Zaugg Switzerland
T. Okamura Japan
Citations per year, relative to Fong Wang Fong Wang (= 1×)
peers
Amy Lin
Countries citing papers authored by Fong Wang
Since
Specialization
Citations
This map shows the geographic impact of Fong Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fong Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fong Wang more than expected).
Fields of papers citing papers by Fong Wang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Fong Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fong Wang. The network helps show where Fong Wang may publish in the future.
Co-authorship network of co-authors of Fong Wang
This figure shows the co-authorship network connecting the top 25 collaborators of Fong Wang. A scholar is included among the top collaborators of Fong Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fong Wang. Fong Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2025). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 394(6). 563–575.
2.
Fizazi, Karim, Nobuaki Matsubara, Douglas Laird, et al.. (2025). Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2.. Journal of Clinical Oncology. 43(16_suppl). 5019–5019.
3.
Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2024). CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 18–18.
4.
Bourlon, María T., Bernard Escudier, Mauricio Burotto, et al.. (2024). Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.. Journal of Clinical Oncology. 42(4_suppl). 362–362.
5.
Powles, Thomas, Robert J. Motzer, Laurence Albigès, et al.. (2023). Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.. Journal of Clinical Oncology. 41(6_suppl). 605–605.
6.
Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2022). A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 18(10). 1185–1198.
7.
Choueiri, Toni K., Laurence Albigès, Thomas Powles, et al.. (2020). A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.. Journal of Clinical Oncology. 38(15_suppl). TPS5102–TPS5102.
8.
Choueiri, Toni K., Laurence Albigès, Thomas Powles, et al.. (2020). 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk. Regular and Young Investigator Award Abstracts. A209.1–A209.
9.
Siemens, D. Robert, Laurence Klotz, Axel Heidenreich, et al.. (2017). Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. The Journal of Urology. 199(1). 147–154.
10.
Slovin, Susan F., William R. Clark, Joan Carles, et al.. (2017). Seizure rates in enzalutamide (ENZ)-treated men with metastatic castration-resistant prostate cancer (mCRPC) at increased risk of seizure: UPWARD study.. Journal of Clinical Oncology. 35(6_suppl). 147–147.
11.
Heidenreich, Axel, Simon Chowdhury, Laurence Klotz, et al.. (2016). Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. European Urology. 71(4). 534–542.
12.
Shore, Neal D., Simon Chowdhury, Arnauld Villers, et al.. (2016). Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet Oncology. 17(2). 153–163.
13.
Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, et al.. (2016). Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 34(2_suppl). 169–169.
14.
Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, et al.. (2016). Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology. 34(18). 2098–2106.
15.
Shore, Neal D., Axel Heidenreich, Arnauld Villers, et al.. (2015). PII-LBA4 TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. The Journal of Urology. 193(4S).
16.
Penson, David F., Andrew Armstrong, Raoul S. Concepcion, et al.. (2015). PII-LBA10 A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER (CRPC): THE STRIVE TRIAL. The Journal of Urology. 193(4S).
17.
Drake, Christopher L., Ron D. Hays, Robert Morlock, et al.. (2014). Development and Evaluation of a Measure to Assess Restorative Sleep. Journal of Clinical Sleep Medicine. 10(7). 733–741.
18.
Wang, Fong, et al.. (2003). Oral Magnesium Oxide Prophylaxis of Frequent Migrainous Headache in Children: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Headache The Journal of Head and Face Pain. 43(6). 601–610.
19.
Laird, Nan M. & Fong Wang. (1990). Estimating rates of change in randomized clinical trials. Controlled Clinical Trials. 11(6). 405–419.
20.
Greger, R., Eberhard Schlatter, Fong Wang, & John N. Forrest. (1984). Mechanism of NaCl secretion in rectal gland tubules of spiny dogfish (Squalus acanthias). Pflügers Archiv - European Journal of Physiology. 402(4). 376–384.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Amy Lin Breakdown of academic impact, for papers by Rajesh Shinghal Breakdown of academic impact, for papers by Maneesha Mehra Breakdown of academic impact, for papers by Kim M. Smits Breakdown of academic impact, for papers by G Gardani Breakdown of academic impact, for papers by Sergio Crispino Breakdown of academic impact, for papers by Kathrin Zaugg Breakdown of academic impact, for papers by T. Okamura